Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse TNFRSF4 /OX40/CD134 Protein, His tag, 100µg  

Recombinant Mouse TNFRSF4 /OX40/CD134 Protein, His tag, 100µg

Recombinant Mouse TNFRSF4 /OX40/CD134 Protein, AA Val 20 - Pro 211, produced in human HEK293 cells, His tag

Synonym
Recombinant Mouse Protein,TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

More details

OX0-M5228-100

Availability: within 7 days

325,00 €

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5

Source
Recombinant Mouse OX40, His Tag (OX0-M5228) is expressed from human 293 cells (HEK293). It contains AA Val 20 - Pro 211 (Accession # P47741-1).
Predicted N-terminus: Val 20

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.2 kDa. The protein migrates as 40-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Retracted: OX40-Fc Fusion Protein Alleviates PD-1-Fc-Aggravated Rheumatoid Arthritis by Inhibiting Inflammatory Response"
Methods In Medicine
Comput Math Methods Med (2023) 2023, 9893203
(2) "The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity"
Yu, Cui, Zhang et al
Cell Mol Immunol (2023)
(3) "The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer"
Choi, Lee, Jin et al
Breast Cancer Res (2023) 25 (1), 134
Showing 1-3 of 2078 papers.